Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Ends Production of Asthma Inhaler

March 7, 2011 6:53 am | News | Comments

AstraZeneca PLC is ending production of one version of its asthma drug Pulmicort immediately because of technical problems in manufacturing.


BMS, WuXi PharmaTech Announce Shanghai Facility

March 7, 2011 6:35 am | News | Comments

Bristol-Myers Squibb Company and WuXi PharmaTech announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.


Ricerca Biosciences and Fulcrum Pharma Collaborate

March 7, 2011 6:27 am | News | Comments

Ricerca Biosciences announced a strategic partnership with Fulcrum Pharma to provide value-added capabilities to biopharmaceutical companies by creating a streamlined and efficient process to move a candidate from development to clinical evaluation.


Observational Research Survey Results

March 7, 2011 6:24 am | News | Comments

PharmaNet Development Group, Inc. announced the results from its fourth semi-annual industry survey on pharmaceutical observational research.


Frontage Laboratories Receives AAALAC Certification

March 7, 2011 6:21 am | News | Comments

Frontage Laboratories, Inc., a provider of preclinical DMPK, CMC drug development and CTM manufacturing, bioanalytical, clinical and consulting services, has achieved AAALAC International accreditation.


DaVita Demonstrates Renal and Scientific Leadership

March 7, 2011 6:18 am | News | Comments

DaVita Clinical Research (DCR), a provider of clinical research and diagnostic laboratory services, opened a central laboratory, expanded its health economics leadership, and participated in top renal industry meetings in 2010.


Celerion adds USP 797-compliant Cleanroom

March 7, 2011 6:15 am | News | Comments

The addition of the USP 797 cleanroom to Celerion's Phase I core capabilities, enables sterile extemporaneous compounding in-house for microtracer studies, giving clients access to quality data earlier in drug development process.


Chromatography Seal

March 4, 2011 7:02 am | Product Releases | Comments

Phenomenex Inc. introduces Easy Seal, an advanced seal for GC columns that addresses common problems with installation and reliability.


Electronic Laboratory Notebook

March 4, 2011 6:58 am | Product Releases | Comments

Accelrys, Inc., a scientific enterprise R&D software and services company, announced the release of the 6.6 version of Symyx Notebook by Accelrys.


WU Installs Ten Eppendorf epMotion Systems

March 4, 2011 6:51 am | News | Comments

Eppendorf announces that The Genome Center at Washington University has purchased and installed 10 additional epMotion 5075 TMX PC systems for its next-generation sequencing sample preparation needs on the Illumina GAIIx and HiSeq platforms.


Sucampo Loses $6.3M In Fourth

March 4, 2011 6:48 am | News | Comments

Sucampo Pharmaceuticals Inc. reported a fourth-quarter loss on lower research and development revenue and higher costs. Revenue on fell on lower funding from partner Takeda after the company completed two late-stage studies on Amitiza.


Protein Modification Could Boost Pancreatic Cancer Drug

March 4, 2011 6:35 am | News | Comments

New research has found that a cell-surface protein called CNT1, which transports cancer-killing drugs into tumor cells, was reduced in function in two thirds of pancreatic tumors.


Drug-Resistant TB May Lead to Cure

March 4, 2011 6:29 am | News | Comments

New findings on how tuberculosis bacteria develop multi-drug tolerance point to ways TB infections might be cured more quickly. The results identify both a mechanism and a potential therapy for drug tolerance that is induced in the TB bacteria by the host cells they infect.


FDA Removes Warning from Letairis Label

March 4, 2011 6:24 am | News | Comments

Gilead Sciences, Inc. announced that the Food and Drug Administration has approved a change to the prescribing information for Letairis, a once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension patients.


EU Clears Onglyza for Kidney-Damaged Patients

March 4, 2011 6:16 am | News | Comments

AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.